A new vaccine that uses the native-like HIV-1 envelope (Env) trimer CH505 and a Toll-like receptor (TLR) 7/8 agonist adjuvant, successfully evaluated in macaques, generated potent polyclonal neutralizing antibodies (nAbs) and a high protection against the infection of the homologous simian-human immunodeficiency virus (SHIV).
Galecto Biotech AB has discovered β-D-galactopyranose compounds acting as galectin-1 (LGALS1) and/or galectin-3 (LGALS3) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, fibrosis and cardiovascular, eye, metabolic, cerebrovascular and inflammatory disorders, among other disorders.
Qilu Regor Therapeutics Inc. has identified (hetero)arylamino-cyclohexyl-sulfonyl derivatives acting as C-C chemokine receptor type 6 (CCR6) antagonists reported to be useful for the treatment of inflammatory bowel disease, Crohn's disease and ulcerative colitis.
Gilead Sciences Inc. has described thienopyrrole compounds acting as Toll-like receptor 7 (TLR7) and/or TLR8 antagonists reported to be useful for the treatment of systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis and inflammatory disorders, among other disorders.
Forge Therapeutics Inc. has synthesized new UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) (bacterial) inhibitors reported to be useful for the treatment of Gram-negative bacterial infections.
More than 70% of individuals with diabetes develop some form of heart disease. Nonischemic diabetic heart disease (NiDHD) is a chronic complication characterized by ventricular dilation and hypertrophy, diastolic dysfunction, and decreased or preserved systolic function, and eventually may result in heart failure.
Proof of concept has been achieved for a therapy for argininosuccinic aciduria consisting of human argininosuccinic lyase (ASL) mRNA encapsulated in lipid nanoparticles (ASL-LNPs).
Researchers from CNRS and the Université d'Orléans presented the discovery of novel inhibitors of LIM kinases (LIMKs) as potential therapeutic candidates for the treatment of osteosarcoma (OS).
China's National Medical Products Administration (NMPA) has cleared CSPC Pharmaceutical Group Limited to conduct clinical trials of TG-103 injection for the treatment of Alzheimer's disease and for the treatment of nonalcoholic steatohepatitis (NASH).
RSS
